# Trade Mark Journal No.2026/026 26 June 2026

## UK00004403250 16 June 2026 (1,42)

CELLVANTAGE

International priority date claimed: 16 December 2025 (Canada) (2443913)

Class 1
  Cell culture reagents for laboratory use; cell culture reagents for scientific and research purposes; antibody reagents for scientific purposes; diagnostic reagents for medical-scientific research use; chemical preparations for the use in the production of medicines; chemical preparations for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes; biochemical preparations for scientific purposes; small molecules for use in increasing viral yield in vaccines and viral medicines; chemical and biochemical products for scientific use and for research, namely, chemical preparations for scientific purposes, laboratory and research use; chemical and biochemical products for scientific use and for research, namely, chemical preparations for scientific purposes, reagents for scientific and research use, in the field of genetics, for the transfer of biological molecules into living cells, integration of foreign nucleic acids into the genome of living cells and production of transfected cells, cell lines, recombinant proteins, peptides, antibodies, viruses, and pseudo-viral particles; chemical or biochemical transfection test kits for virus manufacturing for scientific use and for research containing preparations, agents and reagents.
Class 42
  Biological production in the field of gene therapy and cell therapies; scientific research and analysis in the field of gene and cell therapies; biological production in the field of vaccines; scientific research and analysis in the field of vaccines, process development and evaluation; research and development in the field of vaccines; testing services in the field of vaccines; laboratory research in the field of gene expression; research in the field of gene therapy; research and development in the medical biotechnology field; development of biotechnology; research and development in the pharmaceutical and biotechnology fields.

Virica Biotech Inc.

Representative: J A Kemp LLP